Navigation Links
Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens
Date:4/11/2008

Conference Call Scheduled for 8:30 a.m. ET

ORANGE COUNTY, Calif., April 11 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today it will host a conference call on Wednesday, April 30, 2008, at 8:30 a.m. ET to discuss the company's first quarter 2008 results. Earnings will be released earlier that morning.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

The call may be accessed by dialing (877) 516-3365 or (706) 679-3246 and asking for the Beckman Coulter conference call or reservation number 915339.

There also will be a live webcast of the call. It will be accessible to all investors through Beckman Coulter's website at http://www.beckmancoulter.com or at http://www.streetevents.com. When accessing the webcast through the Beckman Coulter site, select "go to IR" under "Investor Relations" and find the call listed under "What's Ahead." The webcast will be archived on both websites for future on-demand replay.

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating type lease payments, represent more than 78 percent of the company's 2007 revenue of $2.76 billion. For more information, visit '/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
2. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
3. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
4. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
5. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
6. Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
7. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
8. SCAN Health Plan Announces Creation of $205 Million Foundation Dedicated to the Needs of Seniors
9. Almost Family Announces Pricing of 2,250,000 Common Shares
10. Samplify Systems Announces Availability of Samplify for Windows Release 2.6, and Samplify for Windows Embedded Edition, Transforming RF Data Recording Applications with X-COM Systems
11. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3IEEE USA President endorses national innovation strategy 10050 1Utah ethicist heads stem cell panel 10048 1Utah ethicist heads stem cell panel 10048 2Utah ethicist heads stem cell panel 10048 3New beryllium reference material for occupational safety monitoring 10046 1New beryllium reference material for occupational safety monitoring 10046 2